Stocks · News reference
BioStem Technologies Announces It Received Nasdaq Approval For The Company’s Common Stock For Listing On The Nasdaq Capital Market; Co. To Begin Trading On Nasdaq On August 7, 2026 Under The Ticker Symbol "BSEM"
BioStem Technologies Inc. (OTC:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 9:41 PM
- Checked
- Aug 6, 2026, 9:41 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — BioStem Technologies, Inc. (BSEM)
Filed: 2026-08-12 AccNo: 0001193125-26-347211 Size: 459 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarBioStem Technologies Q2 EPS $(0.52), Sales $7.899M Down From $10.963M YoY
BioStem Technologies (NASDAQ:BSEM) reported quarterly losses of $(0.52) per share. The company reported $7.899 million in sales this quarter. This is a 27.95 percent decrease over sales of $10.963 million the same
Read original at benzingaBioStem Technologies Announces Nasdaq Uplisting
BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced that Nasdaq has approved its common stock for listing on The Nasdaq Capital Market. Trading under ticker symbol 'BSEM' is expected to begin on August 7, 2026. The uplisting is expected to expand the company's access to capital, improve market visibility and liquidity, and enhance its ability to attract talent.
Read original at globenewswire-inc